Company news

Mirum Pharmaceuticals, Inc. news in 2025

Mirum Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

December 18, 2025

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

December 7, 2025

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

November 30, 2025

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 24, 2025

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®

November 6, 2025

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 3, 2025

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

October 27, 2025

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

September 7, 2025

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

July 29, 2025

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 18, 2025

Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

May 8, 2025

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

April 29, 2025

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

April 27, 2025

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

April 13, 2025

LIVMARLI Now Approved in Japan for ALGS and PFIC

March 26, 2025

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

February 25, 2025

Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

February 23, 2025

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

February 18, 2025

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

January 12, 2025

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025